Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature-Reference-Cited by-同舟云学术

Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature

Published:2024-02-01 Issue:2 Volume:29 Page:549-558
ISSN:1573-7322
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

McKenzie Taylor,Hale Genevieve M.^ORCID,Miner Amelia,Colón Colón Jean,Evins Garrett,Wade Jasmine

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10741-024-10388-9.pdf

Reference36 articles.

1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 119(6):1453. https://doi.org/10.1093/cvr/cvac013

2. Scheen AJ (2015) Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1):33–59. https://doi.org/10.1007/s40265-014-0337-y

3. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial. Int J Clin Pract 66(5):446–456. https://doi.org/10.1111/j.1742-1241.2012.02911.x

4. Roden M, Merker L, Christiansen AV et al (2015) Safety, tolerability, and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol 14:154. https://doi.org/10.1186/s12933-015-0314-0

5. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases;Metabolism;2024-10